⌘K
t
| TIDM | HEMO |
| Share Price | GBX 771.76-4.63% |
| Market Cap | £49.59m |
Hemogenyx Pharmaceuticals plc announced on 23 February 2026 that it received notices for the exercise of warrants. These exercises are for 50,841 new ordinary shares at prices ranging from 180p to 350p, raising £118,632 for the Company. Admission of these shares to trading on the LSE is expected on or around 27 February 2026, at which point the total number of voting rights will be 6,425,429.
| Date | 23 Feb 2026 |
| Time | 07:00:11 |
| Category | Capital structure |
| ID | 9186T |
23 February 2026
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Exercise of Warrants and Issue of Equity
Introduction
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 50,841 new ordinary shares in the Company (the "Warrant Shares").
The Company has received notices to exercise warrants over 50,841 new Ordinary Shares at exercise prices ranging from 180p to 350p, raising £118,632 for the Company.
Admission and Total Voting Rights
Application will be made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 27 February 2026 ("Admission").
Upon Admission the total number of issued shares and the total number of voting rights in the Company will be 6,425,429.
The above figure of 6,425,429 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
AlbR Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City .
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.